Skip to main content

Table 1 Single nucleotide changes of TP53 mutations in therapy-related versus de novo myelodysplastic syndromes/acute myeloid leukemia (MDS/AML)

From: TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases

Class t-MN, n (%) De novo MDS/AML, n (%)
C:G > A:T 5 (12.2) 1 (1.6)
C:G > G:C 3 (7.3) 6 (9.5)
C:G > T:A 18 (43.9) 35 (55.6)
T:A > A:T 4 (9.8) 3 (4.8)
T:A > C:G 9 (22.0) 12 (19.0)
T:A > G:C 2 (4.9) 6 (9.5)
Total 41 (100) 63 (100)